Research group at the University of Edinburgh using genome editing and targeted protein degradation to study genetic disease and therapy

The University of Edinburgh
Joined December 2013
Today in @NatureGenet, we report a saturation genome editing study that systematically dissects the degron of β-Catenin: one of the most frequently mutated regions of the cancer genome. Collab with @kiddevonline and @DeryaDOzdemir, among many others rdcu.be/e1Tvk
12
1
54
6,278
Andrew Wood retweeted
Out now. A collaboration with Sofia Lövestam, Masato Hasegawa and Sjors Scheres. We report that tau filaments extracted from the brains of individuals with Alzheimer’s disease and corticobasal degeneration breed true in the brains of wild-type mice. nature.com/articles/s41586-0…
2
21
2
76
7,234
Andrew Wood retweeted
Incredibly excited to report today on the determinants of toxicity to systemic therapy in cancer patients. Led by many including Alex Guo, Feiyang Huang, Saksham Mohan, River Walser, and the fearless @ZiadBakouny. Co-led by Wes Tansey and Jian Carrot-Zhang medrxiv.org/content/10.64898…
1
18
4
59
14,135
Andrew Wood retweeted
We're hiring a Postdoctoral Research Associate at @MRC_MBU Cambridge Join our @ARIA_research Precision Mitochondria project with Bitrobius Genetics to develop novel technologies for mitochondrial DNA delivery and genome engineering 🔗 cam.ac.uk/jobs/research-asso… Please share! 🙏
12
1
19
2,606
🔬 New lab preprint: How does the mode of oncogene activation shape PROTAC efficacy? Led by Evelina Gudauskaite, we ask whether stabilising mutations vs transcriptional upregulation have distinct consequences for targeted protein degradation. biorxiv.org/content/10.64898….
1
1
2
135
Using a controlled cellular system (dTAG + TetOn3G), we found: ✅ Stabilising mutations don’t limit PROTAC action—degradation resets protein levels to the same baseline. ❌ Increased transcription raises target protein levels both pre‑ and post‑treatment.
1
45
This reveals a synthesis‑dependent ceiling on degradation, with implications for: • interpreting preclinical degrader data • resistance mechanisms • genotype‑guided therapy design
22
1/ Happy to share important work done with my co-author Andrew Khalil in the labs of Rudolf Jaenisch @WhiteheadInst @MITBiology @MIT and Dave Mooney @Harvard @wyssinstitute trying to assess and fix the major problem of transgene silencing in human ESC/iPSC based work
5
30
6
172
87,425
The big one is finally out!! In this paper, we set out to provide insight into the fundamental question; How do the individual cells from complex tissues regulate their proteomes? Brief summary of our findings 👇 biorxiv.org/content/10.1101/…
6
38
3
197
42,019
Know it before you tag it!! 🏷️🧬
Happy to share our latest work and first manuscript from the Degron Tagging Cluster @MRCMouseNetwork. If you work with protein tags, particularly in tissue biology models, this should be of interest. biorxiv.org/content/10.1101/…
1
3
320
Happy to share our latest work and first manuscript from the Degron Tagging Cluster @MRCMouseNetwork. If you work with protein tags, particularly in tissue biology models, this should be of interest. biorxiv.org/content/10.1101/…
1
1
2
5
1,117
By surveying a series of CRISPR-engineered mice, we found that tags often change protein expression in some tissues but have little effect, or even opposite effects, in others. Why?
1
2
93
We characterise two underlying mechanisms with opposing effects on protein stability and explain their tissue-specificity, providing a rational basis for improved experimental design. Congrats to 1st author Gillian Taylor and all who contributed. Feedback welcome!
1
84